Manganism in the 21st century: The Hanninen lecture

NeuroToxicology

Volumn 45, Issue , 2014, Pages 201-207

  Racette, Brad A ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Dopamine; Manganese; Neurotoxicity; Parkinson disease; Parkinsonism; PET

Indexed keywords

MANGANESE; DOPAMINE;

CHEMICAL ANALYSIS; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); DISEASE ACTIVITY; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; HEALTH HAZARD; HISTORY OF MEDICINE; HUMAN; IMAGE ANALYSIS; INTOXICATION; MANGANISM; MEDICAL LITERATURE; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; QUALITY OF LIFE; REVIEW; BRAIN; CHEMICALLY INDUCED; HISTORY; METABOLISM; MIDDLE AGED; OCCUPATIONAL DISEASE; PATHOLOGY; WELDING;

PARKINSONIA;

BRAIN; DOPAMINE; HISTORY, 21ST CENTURY; HUMANS; MANGANESE POISONING; MIDDLE AGED; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; WELDING;

EID: 84921279854     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.09.007     Document Type: Review

References (79)

1. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-2785.
2. Aggarwal A., Vaidya S., Shah S., Singh J., Desai S., Bhatt M. Reversible parkinsonism and T1W pallidal hyperintensities in acute liver failure. Mov Disord 2006, 21:1986-1990.
3. American Conference of Governmental Industrial Hygienists Documentation of TLVs 1992, ACGIH, Cincinnati.
4. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
5. Brooks D.J. Detection of preclinical Parkinson's disease with PET. Geriatrics 1991, 46:25-30.
6. Brooks D.J., Frey K.A., Marek K.L., Oakes D., Paty D., Prentice R., et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003, 184(Suppl 1):S68-S79.
7. Burkhard P.R., Delavelle J., Du P.R., Spahr L. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol 2003, 60:521-528.
8. Calne D.B., Chu N.S., Huang C.C., Lu C.S., Olanow W. Manganism and idiopathic parkinsonism: similarities and differences. Neurology 1994, 44:1583-1586.
9. Canavan M.M., Cobb W., Drnovsek B. Chronic manganese poisoning: report of a case with autopsy. Archives of Neurologic Psychiatry 1934, 32:501-512.
10. Chang Y., Lee J.J., Seo J.H., Song H.J., Kim J.H., Bae S.J., et al. Altered working memory process in the manganese-exposed brain. Neuroimage 2010, 53:1279-1285.
11. Chang Y., Song H.J., Lee J.J., Seo J.H., Kim J.H., Lee H.J., et al. Neuroplastic changes within the brains of manganese-exposed welders: recruiting additional neural resources for successful motor performance. Occup Environ Med 2010, 67:809-815.
12. Constantinescu R., Richard I., Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord 2007, 22:2141-2148.
13. Cook D.G., Fahn S., Brait K.A. Chronic manganese intoxication. Arch Neurol 1974, 30:59-64.
14. Couper J. On the effects of black oxide of manganese when inhaled into the lungs. Br Ann Med Pharm Vital Stat Gen Sci 1837, 1:41-42.
15. Criswell S.R., Perlmutter J.S., Huang J.L., Golchin N., Flores H.P., Hobson A., et al. Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders. Occup Environ Med 2012, 69:437-443.
16. Criswell S.R., Perlmutter J.S., Crippin J.S., Videen T.O., Moerlein S.M., Flores H.P., Birke A.M., Racette B.A. Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levels. Arch Neurol 2012, 69:394-397.
17. 18F]FDOPA PET in asymptomatic welders with occupational manganese exposure. Neurology 2011, 76:1296-1301.
18. Dietz M.C., Ihrig A., Wrazidlo W., Bader M., Jansen O., Triebig G. Results of magnetic resonance imaging in long-term manganese dioxide-exposed workers. Environ Res 2001, 85:37-40.
19. Dietz M.C., Wrazidlo W., Ihrig A., Bader M., Triebig G. Magnetic resonance tomography of the brain in workers with chronic occupational manganese dioxide exposure. Rofo 2000, 172:514-520.
20. Fahn S., Elton R.L. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1987, 153-163. Macmillan, New York. S. Fahn, C.D. Marsden, M. Goldstein, D.B. Calne (Eds.).
21. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
22. Finkelstein M.M., Jerrett M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res 2007, 104:420-432.
23. Guilarte T.R. Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect 2010, 118:1071-1080.
24. Guilarte T.R., Burton N.C., McGlothan J.L., Verina T., Zhou Y., Alexander M., et al. Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem 2008, 107:1236-1247.
25. Hacker C.D., Perlmutter J.S., Criswell S.R., Ances B.M., Snyder A. Resting state functional connectivity of the striatum in Parkinson's disease. Brain 2012, 135:3699-3711.
26. Harris M.K., Ewing W.M., Longo W., DePasquale C., Mount M.D., Hatfield R., et al. Manganese exposures during shielded metal arc welding (SMAW) in an enclosed space. J Occup Environ Hyg 2005, 2:375-382.
27. Harris R.C., Lundin J.I., Criswell S.R., Hobson A., Swisher L.M., Evanoff B.A., et al. Effects of parkinsonism on health status in welding exposed workers. Parkinsonism Relat Disord 2011, 17:672-676.
28. Hauser R.A., Zesiewicz T.A., Martinez C., Rosemurgy A.S., Olanow C.W. Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Can J Neurol Sci 1996, 23:95-98.
29. Henry J.P., Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol 1989, 38:2395-2404.
30. Hobson A.J., Sterling D.A., Emo B., Evanoff B.A., Sterling C.S., Good L., et al. Validity and reliability of an occupational exposure questionnaire for parkinsonism in welders. J Occup Environ Hyg 2009, 6:324-331.
31. Huang C.C., Chu N.S., Lu C.S., Chen R.S., Calne D.B. Long-term progression in chronic manganism: ten years of follow-up. Neurology 1998, 50:698-700.
32. Huang C.C., Lu C.S., Chu N.S., Hochberg F., Lilienfeld D., Olanow W., et al. Progression after chronic manganese exposure. Neurology 1993, 43:1479-1483.
33. Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology 2005, 64:2021-2028.
34. Kim J., Kim J.M., Kim Y.K., Shin J.W., Choi S.H., Kim S.E., et al. Dopamine transporter SPECT of a liver cirrhotic with atypical parkinsonism. Ind Health 2007, 45:497-500.
35. Kim Y., Jeong K.S., Song H.J., Lee J.J., Seo J.H., Kim G.C., et al. Altered white matter microstructural integrity revealed by voxel-wise analysis of diffusion tensor imaging in welders with manganese exposure. Neurotoxicology 2011, 32:100-109.
36. Kim Y., Kim J.M., Kim J.W., Yoo C.I., Lee C.R., Lee J.H., et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean. Mov Disord 2002, 17:568-575.
37. Kim Y., Kim J.W., Ito K., Lim H.S., Cheong H.K., Kim J.Y., et al. Idiopathic parkinsonism with superimposed manganese exposure: utility of positron emission tomography. Neurotoxicology 1999, 20:249-252.
38. Kim Y., Kim K.S., Yang J.S., Park I.J., Kim E., Jin Y., et al. Increase in signal intensities on T1-weighted magnetic resonance images in asymptomatic manganese-exposed workers. Neurotoxicology 1999, 20:901-907.
39. Koller W.C., Lyons K.E., Truly W. Effect of levodopa treatment for parkinsonism in welders: a double-blind study. Neurology 2004, 62:730-733.
40. Korczynski R.E. Occupational health concerns in the welding industry. Appl Occup Environ Hyg 2000, 15:936-945.
41. Krieger S., Jauss M., Jansen O., Stiehl A., Sauer P., Geissler M., et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. J Hepatol 1997, 27:121-126.
42. Laakso A., Vilkman H., Bergman J., Haaparanta M., Solin O., Syvalahti E., et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry 2002, 52:759-763.
43. Lu C.S., Huang C.C., Chu N.S., Calne D.B. Levodopa failure in chronic manganism. Neurology 1994, 44:1600-1602.
44. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000, 342:1560-1567.
45. Martin W.R.W., Perlmutter J.S. Assessment of fetal tissue transplantation in Parkinson's disease: does PET play a role. Neurology 1994, 44:1777-1780.
46. Meeker J.D., Susi P., Flynn M.R. Manganese and welding fume exposure and control in construction. J Occup Environ Hyg 2007, 4:943-951.
47. Myers J.E., teWaterNaude J., Fourie M., Zogoe H.B., Naik I., Theodorou P., et al. Nervous system effects of occupational manganese exposure on South African manganese mineworkers. Neurotoxicology 2003, 24:649-656.
48. Nandhagopal R., Mak E., Schulzer M., McKenzie J., McCormick S., Sossi V., et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008, 71:1790-1795.
49. Nelson G., Criswell S.R., Zhang J., Murray J., Racette B.A. Research capacity development in South African manganese mines to bridge exposure and neuropathologic outcomes. Neurotoxicology 2012, 33:683-686.
50. Nelson K., Golnick J., Korn T., Angle C. Manganese encephalopathy: utility of early magnetic-resonance-imaging. Br J Ind Med 1993, 50:510-513.
51. Olanow C.W. Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci 2004, 1012:209-223.
52. Park R.M., Schulte P.A., Bowman J.D., Walker J.T., Bondy S.C., Yost M.G., et al. Potential occupational risks for neurodegenerative diseases. Am J Ind Med 2005, 48:63-77.
53. Parkinson Study Group The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 2004, 62:330-332.
54. Parkinson's Study Group DATATOP: a multicenter clinical trial in early Parkinson's disease. Arch Neurol 1989, 46:1052-1060.
55. Perl D.P., Olanow C.W. The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol 2007, 66:675-682.
56. Pujol A., Pujol J., Graus F., Rimola A., Peri J., Mercader J.M., et al. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993, 43:65-69.
57. Racette B.A., Criswell S.R., Lundin J.I., Hobson A., Seixas N., Kotzbauer P.T., et al. Increased risk of parkinsonism associated with welding exposure. Neurotoxicology 2012, 33:1356-1361.
58. Racette B.A., McGee-Minnich L., Moerlein S.M., Mink J.W., Videen T.O., Perlmutter J.S. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 2001, 56:8-13.
59. Racette B.A., Tabbal S.D., Jennings D., Good L., Perlmutter J.S., Evanoff B. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology 2005, 64:230-235.
60. Racette B.A., Antenor J.A., McGee-Minnich L., Moerlein S.M., Videen T.O., Kotagal V., Perlmutter J.S. [18F]FDOPA PET and clinical features in parkinsonism due to manganism. Mov Disord 2005, 20:492-496.
61. Rappaport S.M., Weaver M., Taylor D., Kupper L., Susi P. Application of mixed models to assess exposures monitored by construction workers during hot processes. Ann Occup Hyg 1999, 43:457-469.
62. Rodier J. Manganese poisoning in Moroccan miners. Br J Ind Med 1955, 12:21-35.
63. Sadek A.H., Rauch R., Schulz P.E. Parkinsonism due to manganism in a welder. Int J Toxicol 2003, 22:393-401.
64. Sanotsky Y., Lesyk R., Fedoryshyn L., Komnatska I., Matviyenko Y., Fahn S. Manganic encephalopathy due to ephedrone abuse. Mov Disord 2007, 22:1337-1343.
65. Schoenberg B.S., Anderson D.W., Haerer A.F. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985, 35:841-845.
66. Selikhova M., Fedoryshyn L., Matviyenko Y., Komnatska I., Kyrylchuk M., Krolicki L., et al. Parkinsonism and dystonia caused by the illicit use of ephedrone-a longitudinal study. Mov Disord 2008, 23:2224-2231.
67. Shinotoh H., Snow B.J., Chu N.S., Huang C.C., Lu C.S., Lee C., et al. Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication: a positron emission tomography study. Neurology 1997, 48:1053-1056.
68. Shinotoh H., Vingerhoets F.J., Schulzer M., Snow B.J. The presymptomatic period in a patient with idiopathic parkinsonism. Parkinsonism Relat Disord 1996, 2:127-130.
69. Sikk K., Taba P., Haldre S., Bergquist J., Nyholm D., Askmark H., et al. Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. Acta Neurol Scand 2010, 121:237-243.
70. Spahr L., Butterworth R.F., Fontaine S., Bui L., Therrien G., Milette P.C., et al. Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996, 24:1116-1120.
71. Stepens A., Stagg C.J., Platkajis A., Boudrias M.H., Johansen-Berg H., Donaghy M. White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome. Brain 2010, 133:3676-3684.
72. Susi P., Goldberg M., Barnes P., Stafford E. The use of a task-based exposure assessment model (T-BEAM) for assessment of metal fume exposures during welding and thermal cutting. Appl Occup Environ Hyg 2000, 15:26-38.
73. Tanaka S., Lieben J. Manganese poisoning and exposure in Pennsylvania. Arch Environ Health 1969, 19:674-684.
74. Wang J.D., Huang C.C., Hwang Y.H., Chiang J.R., Lin J.M., Chen J.S. Manganese induced parkinsonism: an outbreak due to an unrepaired ventilation control system in a ferromanganese smelter. Br J Ind Med 1989, 46:856-859.
75. Willis A.W., Evanoff B.A., Lian M., Galarza A., Wegrzyn A., Schootman M., et al. Metal emissions and urban incident Parkinson disease: a community health study of medicare beneficiaries by using geographic information systems. Am J Epidemiol 2010, 172:1357-1363.
76. Willis A.W., Schootman M., Kung N., Evanoff B.A., Perlmutter J.S., Racette B.A. Predictors of survival in patients with Parkinson Disease. Arch Neurol 2012, 69:601-607.
77. Wolters E.C., Huang C.C., Clark C., Peppard R.F., Okada J., Chu N.S., et al. Positron emission tomography in manganese intoxication. Ann Neurol 1989, 26:647-651.
78. Wright W.A., Evanoff B.A., Lian M., Criswell S.R., Racette B.A. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 2010, 34:143-151.
79. Yamada M., Ohno S., Okayasu I., Okeda R., Hatakeyama S., Watanabe H., et al. Chronic manganese poisoning: a neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol (Berl) 1986, 70:273-278.